Author | Lightnews

pharmaphorum

pharmaphorum

@pharmaphorum.bsky.social

94 followers 480 following 900 posts

pharmaphorum.com, and its magazine Deep Dive, is a leading online destination for pharmaceutical industry and healthcare news, insight, and debate

Posts Media Videos Starter Packs

pharmaphorum @pharmaphorum.bsky.social · 20h

#Ipsen has agreed to buy ImCheck and its anti-BTN3A antibody for acute myeloid leukaemia in a deal that could be worth up to €1bn.

pharmaphorum.com/news/ipsen-b...

pharmaphorum @pharmaphorum.bsky.social · 21h

#Takeda has partnered with China's Innovent for a pair of late-stage cancer therapies, in a deal that includes an upfront payment of $1.2bn.

pharmaphorum.com/news/takeda-...

Takeda builds in cancer with monster $11.4bn Innovent deal

Takeda has partnered with China's Innovent for a pair of late-stage cancer therapies, in a deal that includes an upfront payment of $1.2bn.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 22h

Procyon is hoping to launch a diagnostic test next year that will be able to detect people at risk of pancreatic cancer from a urine sample.

pharmaphorum.com/news/uk-star...

UK start-up Procyon has pancreatic cancer test in its sights

Procyon is hoping to launch a diagnostic test next year that will be able to detect people at risk of pancreatic cancer from a urine sample.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 23h

#Galapagos' difficult year has continued with a decision to wind down its cell therapy business as it seeks 'transformative' deals for its drugs unit.

pharmaphorum.com/news/galapag...

Galapagos abandons cell therapy, putting 365 jobs at risk

Galapagos' difficult year has continued with a decision to wind down its cell therapy business as it seeks 'transformative' deals for its drugs unit.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 23h

Novo Nordisk's chairman Helge Lund will step down next month under pressure from the group's controlling shareholder, the #NovoNordisk Foundation.

pharmaphorum.com/news/novo-no...

Novo Nordisk's chairman quits amid Foundation row

Novo Nordisk's chairman Helge Lund will step down next month under pressure from the group's controlling shareholder, the Novo Nordisk Foundation.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 1d

GSK and Spero's cabapenem tebipenem is the first oral antibiotic in the class to show efficacy in complicated urinary tract infections.

pharmaphorum.com/news/gsk-wil...

pharmaphorum @pharmaphorum.bsky.social · 1d

A wireless retinal implant already filed for approval has been shown to restore vision in patients with eye disease geographic atrophy.

pharmaphorum.com/news/joy-ret...

Joy as retinal implant restores sight in geographic atrophy

A wireless retinal implant already filed for approval has been shown to restore vision in patients with eye disease geographic atrophy.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 1d

Akeso/Summit's PD-1xVEGF drug ivonescimab bests a PD-1 inhibitor as first-line therapy in Chinese NSCLC patients, but a bigger test is yet to come.

pharmaphorum.com/news/esmo-iv...

ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer

Akeso/Summit's PD-1xVEGF drug ivonescimab bests a PD-1 inhibitor as first-line therapy in Chinese NSCLC patients, but a bigger test is yet to come.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 1d

Two TROP2-targeting drugs, Datroway and Trodelvy, have new data suggesting they could become first-line options for triple-negative breast cancer.

pharmaphorum.com/news/esmo-da...

ESMO: Datroway, Trodelvy lay claim to frontline TNBC therapy

Two TROP2-targeting drugs, Datroway and Trodelvy, have new data suggesting they could become first-line options for triple-negative breast cancer

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 1d

Has #Roche taken a lead in the oral SERD category of breast cancer therapies with data showing activity in wild-type ESR1 patients?

pharmaphorum.com/news/esmo-cl...

pharmaphorum @pharmaphorum.bsky.social · 2d

#Insmed gets EU recommendation for first non-cystic fibrosis bronchiectasis therapy Brinsupri, plus other CHMP decisions.

pharmaphorum.com/news/chmp-ba...

CHMP backs first drug for lung disease bronchiectasis

Insmed gets EU recommendation for first non-cystic fibrosis bronchiectasis therapy Brinsupri, and other CHMP decisions.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 2d

#Amgen and #AstraZeneca's fast-growing asthma drug Tezspire is now poised to take on rival Dupixent in chronic rhinosinusitis with nasal polyps.

pharmaphorum.com/news/amgen-a...

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Amgen and AstraZeneca's fast-growing asthma drug Tezspire is now poised to take on rival Dupixent in chronic rhinosinusitis with nasal polyps

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 4d

Fresh from a return to #oncology with the FDA approval of #Hernexeos as a treatment for HER2-positive non-small cell #lungcancer (NSCLC), #BoehringerIngelheim is racing to expand its label, with #Bayer in hot pursuit.

pharmaphorum.com/news/esmo-bo...

ESMO: Boehringer, Bayer seek first-line HER2+ NSCLC role

New trial data backs the use of Boehringer Ingelheim's new oral HER2 inhibitor Hernexeos in front-line treatment of HER2+ NSCLC, but Bayer is in hot pursuit.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 4d

Results from the #PATHFINDER2trial of #Grail's #bloodtest for multiple cancers have shown greater efficacy and a lower rate of false alarms than in an earlier trial of the technology.

pharmaphorum.com/news/esmo-gr...

ESMO: Grail's data on cancer blood test firms up

Data from a new phase 3 trial of Grail's blood test for multiple cancers show improved efficacy and a lower rate of false alarms than a prior study.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 4d

#EliLilly's CDK4/6 inhibitor #Verzenio reduced the risk of death by 15.8% when used as adjuvant treatment for early-stage HR-positive, HER2-negative #breastcancer, according the reveal of data from the #monarchEtrial.

pharmaphorum.com/news/esmo-li...

pharmaphorum @pharmaphorum.bsky.social · 5d

ViiV's injectable HIV PrEP Apretude will soon be an alternative for people in England and Wales who cannot use daily oral options.

pharmaphorum.com/news/viivs-b...

ViiV's bimonthly HIV PrEP jab cleared for use by NHS

ViiV's injectable HIV PrEP Apretude will soon be an alternative for people in England and Wales who cannot use daily oral options.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 5d

Researchers have evidence that a sample of menstrual blood could allow a diagnosis of #endometriosis within weeks, rather than years, and guide new drug development.
pharmaphorum.com/news/could-e...

Could endometriosis be diagnosed with a simple test?

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 5d

AI-powered autonomous lab firm Lila Sciences upsizes its Series A to $350m, heading a bumper week for new biotech financings.

pharmaphorum.com/news/lila-sc...

pharmaphorum @pharmaphorum.bsky.social · 5d

Merck KGaA has become the third drugmaker to reach a deal with the Trump administration to cut medicine costs, offering discounts on fertility drugs.

pharmaphorum.com/news/merck-j...

Merck joins the Trump MFN gang with IVF deal

Merck KGaA has become the third drugmaker to reach a deal with the Trump administration to cut medicine costs, offering discounts on fertility drugs.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 5d

The #FDA has named the first products to take advantage of its recently announced Commissioner's national priority voucher programme.

pharmaphorum.com/news/fda-han...

pharmaphorum @pharmaphorum.bsky.social · 6d

Thousands of people in the #UK have joined a #lawsuit against #JohnsonandJohnson, alleging that it knowingly sold #talc products, contaminated with asbestos, that caused #cancer.

pharmaphorum.com/news/jj-face...

J&J faces fresh litigation in UK over talc cancer risks

Thousands of people in the UK have joined a lawsuit against Johnson & Johnson, claiming that it knowingly sold talc products that caused cancer.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 6d

A private equity investment consortium has raised a takeover offer for Denmark's #BavarianNordic, but some shareholders are still reluctant to sell.

pharmaphorum.com/news/bavaria...

Bavarian Nordic urges investors to accept takeover offer

A private equity investment consortium has raised a takeover offer for Denmark's Bavarian Nordic, but some shareholders are still reluctant to sell

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 6d

#NovoNordisk has boosted its pipeline by paying $340m upfront for rights to an #Omeros drug for PNH and other rare blood and kidney disorders.

pharmaphorum.com/news/novo-bu...

Novo builds pipeline again with $2.1bn Omeros deal

Novo Nordisk has boosted its pipeline by paying $340m upfront for rights to an Omeros drug for PNH and other rare blood and kidney disorders

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 7d

A #UK government-backed #initiative to train a new generation of #skilledworkers in #medicinesmanufacturing has been taken up by around 1,200 people since it started 18 months ago.

pharmaphorum.com/news/uks-vr-...

UK's VR-powered medicine maker scheme delivers first results

A UK initiative to train a new generation of workers in medicines manufacturing has been taken up by around 1,200 people since it started last year.

pharmaphorum.com

pharmaphorum @pharmaphorum.bsky.social · 7d

#EliLilly has built the case for its oral #GLP1 agonist #orforglipron with two more phase 3 readouts, including new data showing that it can improve blood glucose compared to a go-to therapy for #type2diabetes.

Lilly says oral GLP-1 could be 'foundational' diabetes drug

Eli Lilly has built the case for its oral GLP-1 orforglipron with two more phase 3 readouts, including a head-to-head win over Farxiga in diabetes.